Latest news with #GBP3.2
Yahoo
21-05-2025
- Business
- Yahoo
IXICO PLC (LSE:IXI) (Q2 2025) Earnings Call Highlights: Strong Revenue Growth and Strategic US ...
Revenue: GBP3.2 million, a 26% growth compared to the first half of last year. Gross Margin: Improved from 40% to 50% compared to the same period last year. EBITDA: Loss of GBP700,000, reduced from GBP1.3 million loss in the previous year. Cash Position: GBP5 million at the end of the first half of the year. Order Book: GBP13.1 million, with full coverage of expected revenues for the year. Capital Investment: GBP300,000 in the first six months, significantly reduced from previous years. Warning! GuruFocus has detected 3 Warning Signs with LSE:IXI. Release Date: May 20, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. IXICO PLC (LSE:IXI) reported a 26% increase in revenue for the first half of 2025, driven by both long-term and short-term contracts. The company achieved a significant improvement in gross margin, increasing from 40% to 50% compared to the same period last year. IXICO PLC has successfully launched a next-generation version of its AI-driven platform, Trial Tracker, which is being deployed with new customers. The company has a strong cash position of GBP5 million and remains debt-free, allowing for strategic investments in innovation and commercial scaling. IXICO PLC has diversified its order book, with 17 clients and 25 different projects, providing a strong foundation for future revenue growth. The biotech sector continues to face macroeconomic challenges, impacting capital access for some clients. Despite revenue growth, IXICO PLC reported an EBITDA loss of GBP700,000 for the first half of the year. The company experienced client descopes or cancellations amounting to GBP2.9 million over the past 12 months. IXICO PLC's order book is heavily reliant on early-phase trials, which carry inherent risks if trials do not progress successfully. The company is still in the process of expanding its presence in the US market, where it faces competition from larger, established players. Q: What percentage of current and future revenue do you expect to be US derived, and how are you positioning against local competitors? A: (Grant Nash, CFO) The majority of clinical trials in neurodegenerative diseases have a significant US element, with over 40% occurring in the US. We are investing in the US market by appointing Terry as our commercial lead and establishing operational and medical capabilities there. While we are smaller in scale compared to US competitors, our technology platform allows us to compete effectively. We are also ensuring a US presence to enhance client perception and engagement. Q: How sticky are your client relationships once a clinical trial begins? Do you typically remain a partner through all phases, or is there a risk of replacement by in-house teams or competitors? A: (Bram Goorden, CEO) Our client relationships are very sticky. Once we start on a Phase 1 or Phase 2 trial, we usually follow our customers into subsequent phases, provided the therapy is successful. There is no risk of replacement by in-house teams, as our analytics of imaging is highly specialized. We also work with large groups that have multiple programs, allowing us to expand within our existing customer base. Q: How much of the GBP3.7 million capital raised in October 2024 has been deployed, and how will future cash be allocated between R&D, platform development, and commercial scaling? A: (Grant Nash, CFO) We have seen a cash outflow of half a million in the first six months of the year. Investments have been made in commercial resources in the US, marketing, corporate development, and medical innovation. Future cash will be allocated to R&D for new analytical capabilities, technology partnerships, and commercial scaling to communicate our innovation effectively to the market. Q: What internal KPIs are most important to management when assessing the success of your innovate, lead, scale strategy? A: (Bram Goorden, CEO) Key KPIs include order book mix, pipeline mix, and financial diversification of deals. We also focus on leading indicators such as innovation productization timelines and resource acquisition. Partnerships and understanding the ecosystem are crucial for identifying new opportunities and ensuring strategic investments align with our goals. Q: How are you addressing the challenge of competing with larger US-based competitors in global trials? A: (Bram Goorden, CEO) We focus on managing global trials effectively, leveraging our experience in handling large Phase 3 trials in the neurodegenerative space. Our strategy includes ensuring we are equipped to manage global trials and maintaining strong client relationships. We emphasize our specialized analytics capabilities, which are not easily replicated by in-house teams or competitors. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Associated Press
28-04-2025
- Business
- Associated Press
Bright Scholar Announces Unaudited Financial Results for the Second Quarter of Fiscal Year 2025
Net income from continuing operations increased 223.6% YoY to GBP3.2 million Management to hold a conference call today at 7:00 a.m. Eastern Time CAMBRIDGE, England and FOSHAN, China, April 28, 2025 /PRNewswire/ -- Bright Scholar Education Holdings Limited ('Bright Scholar,' the 'Company,' 'we' or 'our') (NYSE: BEDU), a global premier education service company, today announced its unaudited financial results for the second quarter of fiscal year 2025 ended February 28, 2025. SECOND QUARTER OF FISCAL YEAR 2025 FINANCIAL HIGHLIGHTS Revenue from continuing operations by Segment[3] MANAGEMENT COMMENTARY Mr. Robert Niu, Chief Executive Officer of Bright Scholar, commented, 'During the second fiscal quarter, we achieved steady progress in executing our 'dual-engine' strategy by advancing both global expansion and student recruitment. These efforts have strengthened the resilience of our Schools business amidst external headwinds while creating a foundation for continued success. Operationally, we maintained stable total enrollment year-over-year at 2,669 students as of March 31, 2025. Notably, we also achieved a strong 14.2% year-over-year improvement in revenue per enrollment at our U.S. schools this quarter, a testament to our premium positioning and operational effectiveness. Meanwhile, our global recruitment efforts continued to gain momentum across key markets, enhancing our pipeline for future growth. As a leading provider of premier international education services, we remain committed to delivering exceptional learning experiences, optimizing operational efficiency, and scaling our global footprint to create enduring value for all stakeholders.' Ms. Cindy Zhang, Chief Financial Officer of Bright Scholar, added, 'We are pleased to report healthy financial results in the second fiscal quarter, reflecting improved operating efficiency and profitability. Our total revenue remained relatively stable year-over-year at GBP43.8 million. Revenues from our Overseas Study Counselling business increased by 6.2% year-over-year to GBP11.9 million. We continue to manage our costs prudently, balancing our growth initiatives with the impact of the macroeconomic environment. Our SG&A expenses decreased by 13.7% year-over-year in absolute amount, while as a percentage of revenue decreasing by 1.2 percentage points to 25.5%. Notably, our net income from continuing operations increased by over 200% year-over-year. In the second half of the fiscal year, we will continue to execute our long-term strategy to balance healthy and sustainable growth while improving profitability.' UNAUDITED FINANCIAL RESULTS FOR THE SECOND FISCAL QUARTER ENDED FEBRUARY 28, 2025 Revenue from Continuing Operations Revenue was GBP43.8 million, compared to GBP48.5 million for the same quarter last fiscal year. Schools: Revenue was GBP26.6 million, compared to GBP27.3 million for the same quarter last fiscal year. Overseas Study Counselling: Revenue was GBP11.9 million, representing an increase of 6.2% from the same quarter last fiscal year. The increase was mainly due to recruitment growth. Others: Revenue was GBP5.3 million, compared to GBP10.0 million for the same quarter last fiscal year. The decrease was mainly due to the contraction of K-12 operation services, which was in line with our expectations. Cost of Revenue from Continuing Operations Cost of revenue was GBP30.7 million, compared to GBP33.6 million for the same quarter last fiscal year. Gross Profit, Gross Margin and Adjusted Gross Profit from Continuing Operations[7] Gross profit was GBP13.2 million, compared to GBP15.0 million for the same quarter last fiscal year. Gross margin was 30.0%, compared to 30.8% for the same quarter last fiscal year. Adjusted gross profit from continuing operations was GBP13.2 million, compared to GBP15.1 million for the same quarter last fiscal year. Selling, General and Administrative (SG&A) Expenses from Continuing Operations Total SG&A expenses were GBP11.2 million, representing a 13.7% decrease from GBP13.0 million for the same quarter last fiscal year. The decrease was mainly due to the improvement in operational efficiency in our Schools business. Operating Income, Operating Margin and Adjusted Operating Income from Continuing Operations Operating income was GBP2.3 million, representing a 7.2% increase from GBP2.2 million for the same quarter last fiscal year. Operating margin was 5.3%, compared to 4.5% for the same quarter last fiscal year. Adjusted operating income from continuing operations increased by 8.1% to GBP2.7 million from GBP2.5 million for the same quarter last fiscal year. Net Income and Adjusted Net Income Net income was GBP3.2 million, representing a 1,045.9% increase from GBP0.3 million for the same quarter last fiscal year. Adjusted net income increased by 179.5% to GBP3.5 million from GBP1.3 million for the same quarter last fiscal year. Adjusted EBITDA[8] Adjusted EBITDA was GBP3.1 million, compared to GBP3.6 million for the same quarter last fiscal year. Net income per Ordinary Share/ADS and Adjusted Net Earnings per Ordinary Share[9]/ADS[10] Basic and diluted net income per ordinary share attributable to ordinary shareholders from continuing operations were GBP0.03 each, compared to GBP0.01 each for the same quarter last fiscal year. Adjusted basic and diluted net income per ordinary share attributable to ordinary shareholders were GBP0.03 each, compared to GBP0.01 each for the same quarter last fiscal year. Basic and diluted net income per ADS attributable to ADS holders from continuing operations were GBP0.11 each, compared to GBP0.03 each for the same quarter last fiscal year. Adjusted basic and diluted net income per ADS attributable to ADS holders were GBP0.12 each, compared to GBP0.04 each for the same quarter last fiscal year. Cash and Working Capital As of February 28, 2025, the Company had cash and cash equivalents and restricted cash of GBP46.3 million, compared to GBP54.3 million as of August 31, 2024. CONFERENCE CALL The Company's management will host an earnings conference call at 7:00 a.m. U.S. Eastern Time (7:00 p.m. Beijing/Hong Kong Time) on April 28, 2025. Dial-in details for the earnings conference call are as follows: Mainland China: 4001-201203 Hong Kong: 800-905945 United States: 1-888-346-8982 International: 1-412-902-4272 Participants should dial in at least 5 minutes before the scheduled start time and ask to be connected to the call for 'Bright Scholar Education Holdings Limited.' Additionally, a live and archived webcast of the conference call will be available on the Company's investor relations website at A replay of the conference call will be accessible after the conclusion of the live call until May 5, 2025, by dialing the following telephone numbers: United States Toll Free: 1-877-344-7529 International: 1-412-317-0088 Replay Passcode: 2410484 CONVENIENCE TRANSLATION The Company's reporting currency is GBP. However, periodic reports made to shareholders will include current period amounts translated into U.S. dollars using the prevailing exchange rates at the balance sheet date for the convenience of readers. Translations of balances in the condensed consolidated balance sheets, the related condensed consolidated statements of operations, and cash flows from GBP into U.S. dollars as of and for the quarter ended February 28, 2025, are solely for the readers' convenience and were calculated at the rate of GBP1.00=US$1.2591, representing the noon buying rate set forth in the H.10 statistical release of the U.S. Federal Reserve Board on February 28, 2025. No representation is made that the GBP amounts could have been, or could be, converted, realized or settled into US$ at that rate on February 28, 2025, or at any other rate. NON-GAAP FINANCIAL MEASURES In evaluating our business, we consider and use certain non-GAAP measures, including primarily adjusted EBITDA, adjusted net income/(loss), adjusted gross profit/(loss) from continuing operations, adjusted operating income/(loss) from continuing operations, adjusted net earnings/(loss) per share attributable to ordinary shareholders/ADS holders basic and diluted as supplemental measures to review and assess our operating performance. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. We define adjusted gross profit/(loss) from continuing operations as gross profit/(loss) from continuing operations excluding amortization of intangible assets. We define adjusted EBITDA as net income/(loss) excluding interest income/(expense), net, income tax expense/(benefit), depreciation and amortization, share-based compensation expenses, and income/(loss) from discontinued operations, net of tax. We define adjusted net income/(loss) as net income/(loss) excluding share-based compensation expenses, amortization of intangible assets, tax effect of amortization of intangible assets, and income/(loss) from discontinued operations, net of tax. We define adjusted operating income/(loss) from continuing operations as operating income/(loss) from continuing operations, excluding share-based compensation expenses and amortization of intangible assets. Additionally, we define adjusted net earnings/(loss) per share attributable to ordinary shareholders/ADS holders, basic and diluted, as adjusted net income/(loss) attributable to ordinary shareholders/ADS holders (net income/(loss) to ordinary shareholders/ADS holders excluding share-based compensation expenses, amortization of intangible assets, tax effect of amortization of intangible assets, and income/(loss) from discontinued operations, net of tax) divided by the weighted average number of basic and diluted ordinary shares or ADSs. We incur amortization expense of intangible assets related to various acquisitions that have been made in recent years. These intangible assets are valued at the time of acquisition and are then amortized over a period of several years after the acquisition. We believe that exclusion of these expenses allows greater comparability of operating results that are consistent over time for the Company's newly-acquired and long-held business, as the related intangibles do not have a significant connection to the growth of the business. Therefore, we provide exclusion of amortization of intangible assets to define adjusted gross profit from continuing operations, adjusted operating income/(loss) from continuing operations, adjusted net income/(loss), and adjusted net earnings/(loss) per share attributable to ordinary shareholders/ADS holders, basic and diluted. In addition, the strategic move to dispose of the non-core businesses is viewed as discontinued operations, which is a non-recurring item. The exclusion facilitates comparisons of our operating performance on a period-to-period basis. Therefore, we provide exclusion of income/(loss) from discontinued operations, net of tax, to define adjusted net income/(loss), adjusted EBITDA, adjusted net earnings/(loss) per share attributable to ordinary shareholders/ADS holders, basic and diluted. We present the non-GAAP financial measures because they are used by our management to evaluate our operating performance and formulate business plans. Such non-GAAP measures include adjusted EBITDA, adjusted net income/(loss), adjusted gross profit/(loss) from continuing operations, adjusted operating income/(loss) from continuing operations, adjusted net earnings/(loss) per share attributable to ordinary shareholders/ADS holders basic and diluted. Non-GAAP financial measures enable our management to assess our operating results without considering the impact of non-cash charges, including depreciation and amortization and share-based compensation expenses, and without considering the impact of non-operating items such as interest income/(expense), net; income tax expense/benefit; share-based compensation expenses; amortization of intangible assets, tax effect of amortization of intangible assets, and without considering the impact of non-recurring item, i.e. income/(loss) from discontinued operations. We also believe that the use of these non-GAAP measures facilitates investors' assessment of our operating performance. The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools. One of the key limitations of using these non-GAAP financial measures is that they do not reflect all items of income and expense that affect our operations. Interest income/(expense), net; income tax expense/benefit; depreciation and amortization; share-based compensation expense; tax effect of amortization of intangible assets have been and may continue to be incurred in our business and are not reflected in the presentation of these non-GAAP measures, including adjusted EBITDA or adjusted net income/(loss). Further, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited. About Bright Scholar Education Holdings Limited Bright Scholar is a premier global education service Group. The Company primarily provides quality international education to global students and equips them with the critical academic foundation and skillsets necessary to succeed in the pursuit of higher education. For more information, please visit: Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, the Company's business plans and development, which can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control, which may cause the Company's actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. IR Contact: Email: [email protected] Phone: +86 (10) 6508-0677/ +1-212-481-2050 Media Contact: Email: [email protected] View original content: SOURCE Bright Scholar Education Holdings Ltd.
